Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 8/20 | 0.69 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207918 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| SCHEMBL14535354 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| SCHEMBL2624908 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| SCHEMBL14288315 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| SCHEMBL12203898 | 0.86 | KCNA5 (0.82) | KCNA5SCN5ATSHRSIGMAR1HRH3 | |
| SCHEMBL2625053 | 0.86 | KCNA5 (0.82) | KCNA5SCN5ATSHRSIGMAR1HRH3 | |
| SCHEMBL2624907 | 0.84 | SLC6A4 (0.56) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| SCHEMBL12810195 | 0.84 | SLC6A4 (0.56) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| Hydrochloric Acid SCHEMBL3134010 | 0.83 | KCNA5 (0.57) | KCNA5SCN5ASLC6A4KCND2KCNH2 | |
| Hydrochloric Acid SCHEMBL5517791 | 0.83 | KCNA5 (0.57) | KCNA5SCN5ASLC6A4KCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163938-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-8163938-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-01-06 | — | — | US | disclosed |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-01-06 | — | — | US | disclosed |
| US-7767830-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2010-08-03 | — | — | US | disclosed |
| US-7767830-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2010-08-03 | — | — | US | disclosed |
| US-7345087-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885SLC6A4 1837/4885 |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885SLC6A4 1837/4885 |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885SLC6A4 1837/4885 |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885SLC6A4 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.